Nutritional status during hospitalization is associated with the long-term prognosis of patients with heart failure

Takuma Takada1, Kentaro Jujo1*, Keiko Inagaki2, Takuro Abe1, Makoto Kishihara1, Shota Shirotani1, Nana Endo1, Shonosuke Watanabe1, Kazuhito Suzuki2, Yuichiro Minami1 and Nobuhisa Hagiwara1

1 Department of Cardiology, Tokyo Women’s Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-0054, Japan; and 2 Department of Cardiology, Kosei Hospital, Tokyo, Japan

Abstract

Aims The CONtrolling NUTritional status (CONUT) score represents the nutritional status of patients with heart failure (HF). Although high CONUT scores on admission are associated with increased risks of cardiovascular (CV) events in patients with HF, the impact of CONUT changes during hospitalization on their long-term prognosis is unclear. This study aimed to investigate the impact of CONUT score changes on the clinical outcomes of patients with HF after discharge.

Methods and results This observational study included 1705 patients hospitalized with HF who were discharged alive. The patients were categorized depending on their CONUT scores at admission and discharge into persistently high, high at admission and normal at discharge, normal at admission and high at discharge, and persistently normal CONUT groups. The primary endpoint was a composite of CV death and readmission for HF after discharge. The primary endpoint occurred in 652 patients (38%) during the median 525 day follow-up period. Patients with persistently high CONUT scores had the highest composite endpoint rate (log-rank trend test: \( P < 0.001 \)). After adjusting for covariates, the hazard ratio for the composite outcome was significantly lower for the patients with high CONUT scores at admission and normal CONUT scores at discharge than for those with persistently high CONUT scores (hazard ratio: 0.69; 95% confidence interval: 0.49–0.98).

Conclusions Nutritional status changes in patients with HF that occurred during hospitalization were associated with CV events after discharge. Improving the nutritional status of patients may improve their clinical outcomes.

Keywords Nutritional status; COntrolling NUTritional status score; Heart failure; Cardiovascular event

Introduction

Despite recent medical advances, the clinical outcomes of patients with heart failure (HF) are particularly poor.1–3 Hospital readmission rates for HF remain high, and they pose a considerable financial burden on healthcare systems.4 There is a strong relationship between HF and malnutrition.5–9 Regardless of the left ventricular ejection fraction or body weight, the prevalence of malnutrition among patients with HF was >50%.5,6 Malnutrition among patients with HF is also related to increased readmission rates for morbidity and mortality associated with cardiovascular (CV) disease.5–9 The most severe forms of malnutrition are cardiac cachexia and a catabolic state, which are associated with poor clinical outcomes, because inflammation and neurohormonal activation are augmented.8,10–12 Therefore, risk stratification requires appropriate evaluations of the nutritional status of patients with HF and especially of aged patients with HF.

The CONtrolling NUTritional status (CONUT) score can identify undernourished patients in hospitalized populations.13 A previous study’s findings showed that a high CONUT score at baseline was associated with long-term all-cause mortality in patients with HF at Stages C and D.7,9 Although most adverse events occur after patients are...
discharged from hospitals, few data describe nutritional assessments of patients with HF at discharge. Furthermore, few studies have focused on the relationships between changes in the nutritional status and the clinical outcomes of patients with HF. Therefore, this study aimed to investigate the impact of CONUT score changes during hospitalization on the clinical outcomes of patients with HF after discharge.

Methods

Study population and endpoints

Initially, this study included consecutive patients who were hospitalized for HF at Tokyo Women’s Medical University Hospital from July 2013 to September 2019. Patients were diagnosed with HF using the Framingham HF diagnostic criteria. We excluded patients who died in hospitals, who were lost to follow-up after discharge, and whose data describing their CONUT scores, at either admission or discharge, were missing. The study population was divided into patients with normal and high CONUT scores at admission; the cut-off score was 2 points, which was based on a previous report. The groups were further divided to create four subgroups according to the CONUT scores at discharge using a cut-off score of 2 points, as follows: (i) persistently high, (ii) high at admission and normal at discharge (high–normal), (iii) normal at admission and high at discharge (normal–high), and (iv) persistently normal. We compared the subgroups’ clinical profiles and long-term prognoses. The study’s primary endpoint was a composite of CV death and readmission for HF. CV death included death caused by an acute myocardial infarction, sudden cardiac death, HF, stroke, CV procedures, CV haemorrhage, and other CV events. The study’s protocol was approved by the hospital’s ethics committee, and patient enrolment was carried out according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients regarding the use of the data from their medical records before study enrolment.

Data collection and follow-up

The patients’ clinical data at admission and discharge were recorded, including their vital signs, New York Heart Association functional classifications, oral medications, laboratory data [i.e. the complete blood count, haemoglobin, albumin, total bilirubin, blood urea nitrogen (BUN), creatinine, electrolyte, C-reactive protein, and brain natriuretic peptide (BNP) levels, estimated glomerular filtration rates (eGFRs), and lipid profiles, including the cholesterol and triglyceride levels], and echocardiographic parameters (i.e. the left atrial diameters, left ventricular end-diastolic diameters, left ventricular ejection fractions, ratios of the early mitral inflow velocity to the early diastolic velocity of the lateral mitral annulus, and right ventricular systolic pressures, which were evaluated during the hospitalization). eGFR was calculated using a previously published formula as follows: eGFR (mL/min/1.73 m²) = 194 × serum creatinine(−1.094) × age(−0.287) × 0.739 (if female). Anaemia was defined as haemoglobin levels of <12.0 g/dL in women and <13.0 g/dL in men. The groups were compared regarding the aforementioned parameters. After hospital discharge, outpatient appointments were scheduled for at least every 2 months.

Nutritional assessments

The CONUT scores were calculated from the serum albumin levels, total peripheral lymphocyte counts, and total cholesterol levels, as described previously. CONUT scores of 0–1 point indicated a normal nutritional status, 2–4 points indicated mild malnutrition, and ≥5 points indicated moderate-to-severe malnutrition (Supporting Information, Table S2). In this study, CONUT scores of 0–1 point were defined as normal CONUT scores, and CONUT scores of ≥2 points were defined as high CONUT scores. Using the Full Nutritional Assessment as the gold standard approach, the CONUT score had a sensitivity of 92.3 and a specificity of 85.0. Additionally, we determined the geriatric nutritional risk index (GNRI) that was calculated as follows: 1.489 × serum albumin (g/L) + 41.7 × (body weight in kg/ideal body weight), and the prognostic nutritional index (PNI) that was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm³). The body mass index was calculated as the weight (kg)/height (m)². These parameters were assessed at the time of hospital admission and discharge.

Statistical analyses

The data are expressed as means and standard deviations or as percentiles in the tables. Fisher’s exact test was used to evaluate the categorical variables. The Mann–Whitney U test was used to compare the continuous variables between two groups. The Kruskal–Wallis test was used to compare the continuous variables among the four groups. The Kaplan–Meier method and log-rank tests were used to compare the event-free ratios among the groups during follow-up. Univariate and multivariable Cox regression analyses were performed to evaluate associations between the baseline characteristics and patient prognoses. Variables were considered clinically significant if they reached a level of significance (P) of <0.05, and they were included in the multivariable model. BNP levels were log-transformed. Another multivariable analysis assessed whether changes in the CONUT scores

DOI: 10.1002/ehf2.13629
during hospitalization, and the patients’ baseline characteristics, namely, age, sex, diabetes mellitus, atrial fibrillation, hypertension, chronic obstructive pulmonary disease, hemodialysis, a history of coronary artery bypass grafting, a family history of heart disease, the left ventricular ejection fraction, and the discharge parameters, namely, the body mass index, heart rate, anemia, eGFR, C-reactive protein level, and prescription of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, or aldosterone antagonist at discharge, were used to adjust the model. Multivariate logistic regression analysis was performed to identify independent factors that could normalize CONUT scores at discharge in patients with high CONUT scores at admission. The factors that were significant in the univariate analysis were also used to adjust the multivariable logistic regression model. A two-sided $P$ value of <0.05 was considered statistically significant. The statistical analyses were performed using R software, Version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

**Study population**

During the study period, 2110 consecutive patients were admitted to our hospital with HF, and 180 (9%) patients died in the hospital (Supporting Information, Figure S1). Of the 1930 patients who were discharged alive, 180 (9%) whose CONUT scores were missing and 45 (2%) who were lost to follow-up were excluded. Ultimately, the data of 1705 patients were analysed. The distributions of the study population’s CONUT scores at admission and discharge are shown in Supporting Information, Figure S2. Among the enrolled patients, 1359 (80%) had high CONUT scores, that is, $\geq 2$ points, at admission and 1347 (79%) had high CONUT scores at discharge. Of the patients, 1213 (71%) were in the persistently high, 146 (9%) were in the high–normal, 134 (8%) were in the normal–high, and 212 (12%) were in the persistently normal CONUT groups (Supporting Information, Figure S1).

**Clinical profiles at admission**

Table 1 shows the study population’s baseline characteristics. Significant differences were evident among the four groups in relation to a diverse range of parameters, except for sex, co-morbidities associated with diabetes mellitus and chronic obstructive pulmonary disease, the ratio between implantable cardioverter defibrillators and cardiac resynchronization therapy, and the total bilirubin level. The normal–high CONUT group had the highest BNP level at admission. The PNI and GNRI correlated negatively with the CONUT score, and the average values of both indices were within the normal ranges in all groups, even in the persistently high CONUT group (Table 1 and Supporting Information, Table S2). Renin–angiotensin–aldosterone system inhibitors and beta-blockers were prescribed to $\geq 50\%$, and statins were prescribed to 35% of the entire study population before hospital admission. The subgroups did not differ regarding the prescription rates for renin–angiotensin–aldosterone system inhibitors, beta-blockers, aldosterone antagonists, inotropes, amiodarone, dipeptidyl peptidase-4 inhibitors, and sodium–glucose cotransporter-2 inhibitors. The patients’ clinical profiles at discharge are summarized in Supporting Information, Table S3.

**Prognosis**

During the median follow-up duration of 525 days (interquartile range: 295–898 days), of the patients who were discharged alive, 289 patients (14%) died as a consequence of any cause, 165 patients (10%) died as a consequence of CV events, and 591 patients (35%) were readmitted for HF. Overall, composite endpoint events occurred in 652 patients (38%) at a median of 199 days (inter-quartile range: 65–421 days) after discharge. Patients with high CONUT scores at admission had a significantly higher rate of the primary endpoint than those with normal CONUT scores at admission (log-rank test: $P < 0.001$) (Figure 1A). Cox regression analysis revealed that a CONUT score of $\geq 2$ points at admission remained an independent predictor of the composite endpoint after adjusting for the covariates that were significant in the univariate analysis (Table 2). Compared with the patients with normal CONUT scores at admission, those with high CONUT scores at admission had significantly higher rates of CV death and readmission for HF (log-rank test: both $P < 0.001$). When the patients were separated into groups with a normal nutritional status (CONUT score: 0–1 point), mild malnutrition (CONUT score: 2–4 points), or moderate-to-severe malnutrition (CONUT score: $\geq 5$ points) at admission, the patients with a normal nutritional status showed the lowest composite endpoint rate. The groups of patients with mild malnutrition or moderate-to-severe malnutrition did not differ regarding the composite endpoint rate (Supporting Information, Figure S3). Compared with the patients with CONUT scores of $< 2$ points at discharge, the patients with CONUT scores of $\geq 2$ points had a significantly higher primary endpoint rate (log-rank test: $P < 0.001$) (Figure 1B). The Cox regression analyses that incorporated the discharge parameters consistently showed that a high CONUT score at discharge was associated with the composite endpoint after adjusting for covariates (Supporting Information, Table S4).
Table 1  Baseline characteristics in patients with high or normal CONUT scores at admission or discharge

| Variables at admission | Admission–discharge CONUT |
|------------------------|--------------------------|
|                        | All patients n = 1705    | High-normal n = 146 | Normal-high n = 134 | Normal-normal n = 212 | P value |
| Age (years)             | 71 ± 15                  | 73 ± 14              | 70 ± 14              | 62 ± 15               | <0.001  |
| Male                   | 1099 (64%)               | 88 (60%)             | 86 (64%)             | 140 (66%)             | 0.39    |
| BMI (kg/m^2)           | 23.7 ± 4.7               | 24 ± 4.9             | 25 ± 5.1             | 25 ± 5.2              | <0.001  |
| Hypertension           | 1143 (67%)               | 92 (63%)             | 101 (75%)            | 128 (60%)             | 0.020   |
| Diabetes               | 683 (40%)                | 56 (38%)             | 51 (38%)             | 73 (34%)              | 0.24    |
| Insulin-requiring      | 196 (11%)                | 16 (11%)             | 12 (6%)              | 7 (5%)                | 0.01    |
| Dyslipidaemia          | 858 (50%)                | 75 (51%)             | 86 (64%)             | 117 (55%)             | 0.001   |
| Smoking history        | 843 (49%)                | 68 (47%)             | 71 (53%)             | 108 (51%)             | 0.71    |
| COPD                   | 86 (5%)                  | 71 (6%)              | 6 (4%)               | 6 (3%)                | 0.086   |
| Family history of IHD  | 433 (25%)                | 42 (29%)             | 39 (29%)             | 69 (33%)              | 0.016   |
| Atrial fibrillation    | 852 (50%)                | 62 (42%)             | 59 (44%)             | 76 (36%)              | <0.001  |
| Prior PCI              | 334 (20%)                | 21 (14%)             | 27 (20%)             | 18 (8%)               | <0.001  |
| Prior CABG             | 138 (8%)                 | 7 (5%)               | 11 (8%)              | 4 (2%)                | <0.001  |
| NYHA IV                | 1258 (74%)               | 113 (77%)            | 97 (72%)             | 104 (49%)             | <0.001  |
| Prior stroke           | 284 (17%)                | 15 (10%)             | 20 (15%)             | 25 (12%)              | 0.111   |
| Haemodialysis          | 127 (7%)                 | 110 (9%)             | 11 (8%)              | 2 (1%)                | <0.001  |
| PM                     | 232 (14%)                | 187 (15%)            | 18 (12%)             | 17 (8%)               | 0.003   |
| ICD                    | 235 (14%)                | 170 (14%)            | 21 (16%)             | 32 (15%)              | 0.18    |
| CRT                    | 183 (11%)                | 137 (11%)            | 14 (10%)             | 21 (10%)              | 0.58    |
| Systolic BP (mmHg)     | 126 ± 28                 | 126 ± 26             | 134 ± 34             | 126 ± 27              | 0.052   |
| Diastolic BP (mmHg)    | 70 ± 18                  | 74 ± 22              | 73 ± 19              | 73 ± 18               | <0.001  |
| Heart rate (b.p.m.)    | 83 ± 22                  | 82 ± 21              | 88 ± 28              | 84 ± 23               | 0.049   |
| Cardiacorhatic ratio (%)| 61 ± 7.9                | 61 ± 8.1             | 59 ± 6.3             | 58 ± 7.3              | <0.001  |
| Echocardiography       |                          |                      |                     |                      |         |
| LVEF (%)               | 40 ± 13                  | 38 ± 13              | 39 ± 13              | 38 ± 12               | 0.007   |
| LVDd (mm)              | 56 ± 11                  | 58 ± 11              | 56 ± 10              | 58 ± 11               | <0.001  |
| LVAD (mm)              | 48 ± 11                  | 48 ± 12              | 46 ± 7.5             | 45 ± 9.1              | <0.001  |
| eGFR (mL/min/1.73 m^2) | 45 ± 31                  | 53 ± 49              | 40 ± 20              | 59 ± 33               | <0.001  |
| Sodium (mEq/L)         | 139 ± 4                  | 140 ± 3.3            | 140 ± 3.6            | 139 ± 3.6             | <0.001  |
| Potassium (mEq/L)      | 4.4 ± 0.6                | 4.4 ± 0.6            | 4.4 ± 0.6            | 4.4 ± 0.6             | <0.001  |
| T-Chol (mg/dL)         | 161 ± 40                 | 172 ± 34             | 186 ± 34             | 200 ± 38              | <0.001  |
| LDL-Chol (mg/dL)       | 90 ± 33                  | 100 ± 29             | 107 ± 29             | 121 ± 33              | <0.001  |
| Triglyceride (mg/dL)   | 53 ± 17                  | 52 ± 19              | 55 ± 16              | 55 ± 17               | 0.02    |
| CRP (mg/dL)            | 98 ± 63                  | 108 ± 59             | 124 ± 102            | 136 ± 78              | <0.001  |
| BNP (pg/mL)            | 908 ± 1053               | 842 ± 678            | 994 ± 1223           | 507 ± 535             | <0.001  |
| CONUT score            | 3.5 ± 2.3                | 2.9 ± 1.3            | 0.7 ± 0.5            | 0.5 ± 0.5             | <0.001  |
| at admission           |                          |                      |                     |                      |         |
| PNI score at admission | 44 ± 7.5                 | 44 ± 5.1             | 51 ± 7.8             | 53 ± 5.7              | <0.001  |
| GNRI score at admission| 100 ± 12                 | 101 ± 11             | 106 ± 12             | 110 ± 11              | <0.001  |
| Medication at admission|                          |                      |                     |                      |         |
| ACEI/ARB               | 1046 (61%)               | 87 (60%)             | 85 (63%)             | 117 (55%)             | 0.22    |
| Beta-blocker           | 956 (56%)                | 70 (48%)             | 79 (59%)             | 108 (51%)             | 0.050   |
| Aldosterone            | 616 (36%)                | 51 (35%)             | 56 (37%)             | 82 (39%)              | 0.11    |
| Thiazide               | 218 (13%)                | 9 (6%)               | 12 (9%)              | 22 (10%)              | 0.008   |
| Furosemide             | 1043 (61%)               | 73 (50%)             | 68 (51%)             | 118 (56%)             | <0.001  |
| Furosemide dose (mg/day)| 37 ± 24                  | 33 ± 20              | 35 ± 27              | 33 ± 19               | 0.16    |
| Calcium channel blocker| 458 (27%)                | 38 (26%)             | 47 (35%)             | 51 (24%)              | 0.15    |
| Inotrope               | 257 (15%)                | 17 (12%)             | 18 (13%)             | 29 (14%)              | 0.49    |

(Continues)
Subgroup comparisons

During follow-up, the composite endpoint occurred in 522 patients (43%) in the persistently high, 41 patients (31%) in the normal–high, 39 patients (27%) in the high–normal, and 50 patients (24%) in the persistently normal CONUT groups. The Kaplan–Meier analysis showed that the persistently high CONUT group had the highest rate and the persistently normal CONUT group had the lowest rate of the composite endpoint (log-rank trend test: $P < 0.001$) (Figure 2). Of the four subgroups, the persistently high CONUT group showed the highest rates of CV death and HF readmission (both $P < 0.001$). After adjusting the model for co-morbidities and discharge parameters, the persistently high CONUT group and the normal–high CONUT group did not differ in the hazard ratio (HR) for the composite outcome (HR: 0.77; 95% confidence interval: 0.54–1.09; $P = 0.14$), and compared with the persistently high CONUT group, the high–normal CONUT group had a significantly lower HR for the composite outcome (HR: 0.69; 95% confidence interval: 0.49–0.98; $P = 0.04$) (Table 3). When the patients were separated into two groups according to the presence of high and low CONUT scores during the index hospitalization, the primary endpoint rate did not differ between the groups (log-rank test: $P = 0.73$) (Supporting Information, Figure S4). Furthermore, when the study population was divided into two groups according to the phenotype of HF, HF with reduced ejection fraction and HF with preserved left ventricular ejection...
The current study revealed that the CONUT scores at admission were related to poor clinical outcomes, which is consistent with previous reports. Additionally, our study focused on changes in nutritional status during hospitalization. The principal findings were (i) patients with high CONUT scores at admission and normal CONUT scores at discharge had significantly better clinical outcomes than those whose CONUT scores were persistently high.

The principal findings were (i) patients with high CONUT scores at admission and normal CONUT scores at discharge had significantly better clinical outcomes than those whose CONUT scores were persistently high.

### Discussion

#### Study findings

This study’s findings demonstrated the long-term clinical prognoses of patients with HF according to changes in their nutritional status during hospitalization. The principal findings were (i) patients with high CONUT scores at admission and discharge had poor long-term clinical outcomes and (ii) patients with high CONUT scores at admission and normal CONUT scores at discharge had significantly better clinical outcomes than those whose CONUT scores were persistently high.

The current study revealed that the CONUT scores at admission were related to poor clinical outcomes, which is consistent with previous reports. Meanwhile, few reports refer to CONUT scores at discharge; Yoshihisa et al. showed that high CONUT scores at discharge were associated with all-cause mortality in patients with HF, consistent with the current findings. Additionally, our study focused on changes in nutritional status. We have shown that the nutritional

### Table 2 Cox regression analysis for the composite of cardiovascular death and heart failure readmission using the baseline parameters

| Variables                      | Univariate HR | 95% CI | P value | Multivariate HR | 95% CI | P value |
|-------------------------------|---------------|--------|---------|-----------------|--------|---------|
| Age                           | 1.02          | 1.01–1.03 | <0.001 | 1.01 | 1.00–1.02 | 0.06 |
| Male                          | 1.04          | 0.89–1.23 | 0.60 | 0.95 | 0.93–0.98 | <0.001 |
| BMI                           | 0.95          | 0.93–0.96 | <0.001 | 1.54 | 1.20–1.99 | <0.001 |
| NYHA IV                       | 1.58          | 1.31–1.90 | <0.001 | 1.54 | 1.20–1.99 | <0.001 |
| Atrial fibrillation           | 1.46          | 1.25–1.71 | <0.001 | 1.11 | 0.89–1.38 | 0.33 |
| Diabetes                      | 1.24          | 1.07–1.45 | <0.001 | 1.34 | 1.09–1.65 | 0.006 |
| COPD                          | 1.33          | 0.96–1.85 | 0.085 | 0.98 | 0.65–1.9 | 0.41 |
| Haemodialysis                 | 0.88          | 0.65–1.9 | 0.41 | 0.99 | 0.71–1.4 | 0.20 |
| Prior CABG                    | 1.42          | 1.10–1.83 | 0.006 | 1.00 | 0.71–1.39 | 0.98 |
| Family history of IHD         | 1.05          | 0.88–1.30 | 0.61 | 0.99 | 0.98–1.00 | 0.24 |
| LVEF                          | 0.99          | 0.99–1.00 | 0.008 | 0.99 | 0.99–1.00 | 0.02 |
| Systolic BP per 1 mmHg        | 0.99          | 0.99–1.00 | <0.001 | 1.00 | 0.99–1.00 | 0.001 |
| Heart rate per 1 b.p.m.       | 0.99          | 0.99–1.00 | <0.001 | 0.99 | 0.99–1.00 | 0.001 |
| Log-transformed BNP           | 1.49          | 1.26–1.76 | <0.001 | 1.15 | 0.88–1.51 | 0.30 |
| eGFR                          | 1.02          | 1.01–1.02 | <0.001 | 1.01 | 1.00–1.02 | 0.001 |
| eGFR                          | 0.99          | 0.99–1.00 | <0.001 | 1.00 | 0.99–1.01 | 0.87 |
| Anaemia                       | 1.75          | 1.48–2.06 | <0.001 | 0.97 | 0.76–1.23 | 0.78 |
| Sodium                        | 0.95          | 0.94–0.97 | <0.001 | 0.99 | 0.97–1.02 | 0.61 |
| CP                           | 0.99          | 0.97–1.02 | 0.65 | 1.00 | 1.00–1.01 | 0.26 |
| Furosemide dose               | 1.01          | 1.00–1.01 | <0.001 | 1.00 | 1.00–1.01 | 0.26 |
| Statin                        | 1.11          | 0.95–1.30 | 0.20 | 1.00 | 1.00–1.01 | 0.26 |
| ACE/ARB                      | 1.23          | 1.09–1.51 | 0.002 | 1.16 | 1.13–2.16 | 0.007 |
| Beta-blocker                  | 1.37          | 1.17–1.61 | <0.001 | 1.07 | 0.85–1.36 | 0.55 |
| Aldosterone antagonist        | 1.70          | 1.46–1.98 | <0.001 | 1.49 | 1.19–1.88 | <0.001 |

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; b.p.m., beats per minute; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; CI, confidence interval; CONUT, CONtrolling NUTritional status; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification.

In univariate Cox regression analysis, age, BMI, NYHA Class IV, atrial fibrillation, diabetes mellitus, history of CABG, LVEF, systolic BP, heart rate, BNP, eGFR, anaemia, serum sodium, daily furosemide dose, and high CONUT score ≥2 at admission were associated with the incidence of composite endpoint. The prescription of statin at admission and haemodialysis were not statistically related to the composite endpoint. Even after adjusting for significantly related factors in univariate analysis, CONUT score ≥2 at admission remained the independent predictor for the composite endpoint.

#### Predicting normalization of CONtrolling NUTritional status scores at discharge

Logistic regression analysis for the normalization of CONUT scores in patients with high scores at admission revealed that having a younger age, a low BUN level, no anaemia, no statin use, or a low CONUT score at admission was independently associated with the normalization of CONUT scores at discharge (Table 4). In contrast, Supporting Information, Table S5 describes the factors related to changes in the nutritional status from normal CONUT scores at admission to high CONUT scores at discharge. Low eGFR and high CONUT scores at admission were independent predictors for high CONUT scores at discharge in patients with normal CONUT scores at admission (Supporting Information, Table S5).
status of patients with HF can change during hospitalization and that the patients in subgroups defined according to the CONUT scores at admission and discharge had different clinical profiles and prognoses after discharge, a novel finding.

### Nutritional assessment

We selected the CONUT score to represent the nutritional status of hospitalized patients with HF in the current study, and given that it comprises the results from blood tests only, the CONUT score should be objective and reproducible. In addition, the CONUT score accurately represents a patient’s nutritional status, and it predicts short- and long-term prognoses, because the albumin levels and lymphocyte counts may be associated with a patient’s prognosis at different time points.

The PNI and GNRI correlated negatively with the CONUT score, but the PNI and GNRI at admission were within their normal ranges when the CONUT score was abnormal (Supporting Information, Table S2). A lower GNRI at admission is associated with higher in-hospital and long-term mortality rates in patients hospitalized with HF. Although the GNRI is useful for prognostic risk stratification, patients’ body weights cannot always be determined during the acute phase of HF because the patients are intubated, their vital signs are monitored continuously, and mechanical circulatory support systems are used. Unlike the CONUT score, the PNI

---

**Figure 2** Composite outcome after discharge among the four subgroups categorized according to the CONtrolling NUTritional status (CONUT) scores at admission and discharge. Kaplan–Meier curve of the composite outcome in the four subgroups categorized according to the CONUT scores at admission and discharge using a cut-off score of 2 points.

**Table 3** Multivariate analysis by Cox regression of CV death and HF readmission

| Variables          | Event rate (%) | Age-sex-adjusted HR | 95% CI | P value | Multivariate-adjusted HR | 95% CI | P value |
|--------------------|----------------|---------------------|--------|---------|--------------------------|--------|---------|
| At admission–discharge |                |                     |        |         |                          |        |         |
| High–high CONUT    | 43             | 0.61                | 0.45–0.85 | 0.003   | 0.77                     | 0.54–1.09 | 0.14   |
| Normal–high CONUT  | 31             | 0.56                | 0.40–0.77 | <0.001  | 0.69                     | 0.49–0.98 | 0.04   |
| High–normal CONUT  | 27             | 0.48                | 0.35–0.64 | <0.001  | 0.58                     | 0.39–0.86 | 0.008  |
| Normal–normal CONUT| 24             | 0.48                | 0.35–0.64 | <0.001  | 0.58                     | 0.39–0.86 | 0.008  |

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; CONUT, CONtrolling NUTritional status; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio.

Patients’ baseline characteristics, namely, age, sex, diabetes mellitus, atrial fibrillation, hypertension, chronic obstructive pulmonary disease, haemodialysis, a history of coronary artery bypass grafting, a family history of heart disease, the left ventricular ejection fraction, and the discharge parameters, namely, the body mass index, heart rate, anaemia, eGFR, and C-reactive protein level, ACEi/ARB, beta-blocker, and aldosterone antagonist, were used to adjust the model.
does not account for the total cholesterol level, and given that the total cholesterol level is an established long-term prognostic predictor,\(^2\) the PNI might be of less prognostic value than the CONUT scoring system in relation to long-term outcomes. Additionally, the PNI might underestimate a slightly malnourished patient’s status, because it does not include criteria that account for mild malnutrition.\(^3\) The CONUT score may reflect low plasma cholesterol levels resulting from statin therapy,\(^5\) yet when statin treatment was considered in the current study, the CONUT score remained an independent predictor of the long-term prognoses of patients hospitalized with HF. Classifying the patients into three strata according to their CONUT scores at admission showed that the risk of the composite endpoint was the lowest for the patients whose nutritional status was normal and that the risk of the composite endpoint was comparable for the patients with mild or moderate-to-severe malnutrition (Supporting Information, Figure S3). Therefore, these findings show that mild malnutrition should not be overlooked, and they suggest that stratifying patients according to risk using a cut-off score of 2 points may be acceptable for assessing the prognoses of patients with HF. Patients with high CONUT scores at admission had worse CV prognoses after discharge than those with normal CONUT scores at admission, and within this high-risk population, the patients in the persistently high CONUT group had worse prognoses than the patients in the high–normal CONUT group, regardless HF phenotype. We expected the patients in the persistently normal and the high–normal CONUT groups to have better clinical outcomes. Surprisingly, the patients in the normal–high and persistently high CONUT groups had similar prognoses; the normal–high CONUT group had the highest BNP level at admission, which may have influenced these results. Meanwhile, increases or decreases in the CONUT scores during hospitalization were not associated with the prognosis. Hence, patients with HF must be stratified according to the presence or absence of malnutrition at admission, and if malnutrition is evident, it is also important to check for improvements during hospitalization.

### Clinical implications

Regarding the characteristics of patients whose nutritional status may improve at discharge, the multivariate logistic regression analysis showed that absence of anaemia, lower BUN levels, no statin use, and lower CONUT scores at admission were independent predictors of a normal CONUT score at discharge. Anaemia and high BUN levels are also adversely associated with mortality among patients with HF.\(^2\)\(^1\)\(^4\)\(^2\)\(^5\)\(^2\)\(^5\)\(^2\)\(^5\) Consistent with the current findings. Whether these factors cause malnutrition is unclear, but the PNI and CONUT scores correlate with the haemoglobin level at admission.\(^8\)\(^2\)\(^6\) We considered that to improve anaemia, it was necessary to detect the appropriate cause of anaemia, including ferritin levels; the

---

**Table 4 Logistic regression analysis in patients with high CONUT at admission for normal CONUT score at discharge (n = 1359)**

| Variables                      | Univariate |         |         |         |         |         |         |         |         |
|--------------------------------|------------|---------|---------|---------|---------|---------|---------|---------|---------|
|                                | OR         | 95% CI  | P value | OR      | 95% CI  | P value |
| Age per 1 year                 | 0.97       | 0.96–0.98 | <0.001 | 0.98   | 0.97–1.00 | 0.04   |
| Male                           | 0.83       | 0.58–1.18 | 0.29   | 0.85   | 0.52–1.38 | 0.14   |
| BMI                            | 1.04       | 1.00–1.08 | 0.03   | 1.02   | 0.98–1.07 | 0.38   |
| Diabetes mellitus              | 0.88       | 0.62–1.25 | 0.47   | 1.07   | 0.80–1.42 | 0.73   |
| COPD                           | 0.33       | 0.11–1.09 | 0.07   | 0.48   | 0.22–1.04 | 0.06   |
| Prior CABG                     | 0.48       | 0.22–1.04 | 0.06   | 0.56   | 0.28–1.17 | 0.04   |
| Family history of IHD          | 1.33       | 0.91–1.94 | 0.15   | 1.71   | 1.22–2.39 | 0.001  |
| Atrial fibrillation            | 0.63       | 0.65–0.89 | 0.009  | 0.70   | 0.55–0.89 | 0.001  |
| Haemodialysis                  | 0.28       | 0.10–0.77 | 0.01   | 0.35   | 0.20–0.62 | 0.001  |
| NYHA IV                        | 0.98       | 0.65–1.47 | 0.91   | 0.91   | 0.72–1.16 | 0.54   |
| LVEF per 1%                    | 0.99       | 0.97–1.00 | 0.050  | 0.91   | 0.72–1.15 | 0.49   |
| Systolic BP per 1 mmHg         | 1.00       | 0.99–1.01 | 0.68   | 1.00   | 0.99–1.01 | 0.73   |
| Heart rate per 1 b.p.m.        | 1.01       | 1.00–1.02 | 0.01   | 1.00   | 0.99–1.01 | 0.73   |
| BUN per 1 mg/dL                | 0.96       | 0.95–0.97 | <0.001 | 0.97   | 0.95–0.99 | 0.01   |
| Log-transferred BNP            | 1.16       | 0.80–1.68 | 0.45   | 1.25   | 0.90–1.75 | 0.17   |
| eGFR per 1 mL/min/1.73 m\(^2\) | 1.01       | 1.00–1.01 | <0.001 | 1.00   | 0.99–1.01 | 0.73   |
| Anaemia                        | 0.23       | 0.16–0.33 | <0.001 | 0.56   | 0.36–0.90 | 0.01   |
| Total bilirubin per 1 mg/dL    | 1.10       | 0.89–1.36 | 0.39   | 1.30   | 1.08–1.56 | 0.005  |
| CRP per 1 mg/dL                | 0.96       | 0.90–1.03 | 0.28   | 1.00   | 0.96–1.05 | 0.45   |
| Sodium per 1 mEq/L             | 1.07       | 1.02–1.11 | 0.004  | 1.14   | 1.02–1.26 | 0.04   |
| Statin                         | 0.56       | 0.38–0.83 | 0.004  | 0.52   | 0.32–0.85 | 0.008  |
| Furosemide daily dose per 1 mg | 0.99       | 0.98–1.00 | 0.13   | 0.60   | 0.42–0.86 | 0.002  |
| CONUT score at admission       | 0.53       | 0.45–0.62 | <0.001 | 0.55   | 0.46–0.67 | <0.001 |

**b.p.m., beats per minute; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; CI, confidence interval; CONUT, CONTrolling NUTritional status; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification; OR, odds ratio.**
insufficient erythropoiesis with chronic kidney disease; or the deficiency of iron, copper, zinc, pyridoxine, tocopherol, cobalamin, folic acid, or ascorbic acid, which were also generally related to the nutritional status. However, these results could indicate that patients with both HF and these characteristics at admission were experiencing cachexia or their general condition was poor, because anaemia is included in the definition of cachexia.\textsuperscript{27} Regarding statin use, two large, randomized studies’ findings have shown that statins are not associated with better clinical outcomes in patients with HF.\textsuperscript{28,29} In addition, some guidelines do not primarily recommend statin therapy for patients with HF.\textsuperscript{30} Therefore, if malnourished patients with HF have begun statin therapy, the timing of the statin prescription should be evaluated carefully.

Although an appropriate strategy for improving a patient’s nutritional status remains unclear, this study’s findings suggest that if it is poor at admission and it improves to a normal nutritional status when the patient is discharged from hospital, their prognosis will be ameliorated. There are no standard protocols for improving nutritional status because each patient’s nutritional status and background vary. However, nutritional assessment, counselling, and education are performed at various points by the nutrition support team (NST) in Japan during the index hospitalization, during which the patients’ nutritional status, severity of HF, frailty, age, family support environment or nursing facility, and swallowing and mastication function are assessed. The NST comprehensively decides the appropriate food form or stiffness as well as the optimal food administration route (i.e. oral, intravenous, or tube feeding). Recently, Hersberger et al. demonstrated that individual nutritional support for hospitalized patients with chronic HF improved their mortality.\textsuperscript{31} Therefore, we should carefully assess the nutritional status of patients at admission, strive to improve their nutritional status, and re-evaluate their nutritional status at discharge. Additionally, a multidisciplinary approach that involves nutritionists is crucial to achieve better clinical outcomes.

**Limitations**

This was a retrospective study performed in a single centre. We did not evaluate the patients’ muscle volumes, exercise capacities, fatty acid metabolisms, iron dynamics, or sarcopenia. Although some patients received nutritional assessment and counselling through the NST during hospitalization, there were no data regarding their nutritional status or compliance after discharge. To date, very few publications have described nutritional interventions that can improve the prognoses of patients with HF.\textsuperscript{32} Indeed, some factors such as age, BUN level, anaemia, and CONUT score at admission were associated with an improvement in malnutrition at discharge; however, we could not propose the effect of these factors on malnutrition or an approach that would improve the nutritional status of a patient and reduce the CONUT score based on the findings from this study. A change in the CONUT score might only represent the nutritional status of the patients who have reserves for prognostic improvement. Although we grouped the patients according to their CONUT scores using a cut-off score of 2 points to ensure we did not miss minor malnutrition, other cut-off values were not examined. Further large prospective investigations are needed to determine the best management strategy for patients with HF.

**Conclusions**

Changes in the nutritional status of patients with HF during hospitalization were associated with CV death or HF readmission after discharge. To stratify patients with HF appropriately according to risk, their nutritional status must be re-evaluated after initial treatment, and nutritional interventions should be considered for this refractory population.

**Acknowledgement**

We would like to thank Editage (www.editage.jp) for English-language editing.

**Conflict of interest**

None declared.

**Funding**

This study was not supported financially by any company, grant, or fund.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Assessment of malnutrition by Controlling Nutritional Status (CONUT) score.

Table S2. Nutritional status at admission in patients with persistently high CONUT score during hospitalization.

Table S3. Patients profile at discharge in high or normal CONUT at admission and discharge.

Table S4. Cox regression analysis for the composite of cardiovascular death and heart failure readmission using the parameters at discharge.
Table S5. Logistic regression analysis in patients with normal CONUT at admission for high CONUT score at discharge (n = 346).

Figure S1. Study population CONUT = CONtrolling NUTritional status; HF = heart failure.

Figure S2. Distribution of CONUT score Number of patients at each CONUT score at admission (blue) and discharge (red). CONUT = controlling nutritional status.

Figure S3. Combined outcome after discharge among 3 subgroups classified with the nutritional status at admission. Note: Division of the study population into three groups with normal nutritional status (CONUT 0–1 points), mild malnutrition (CONUT score 2–4 points) and moderate to severe malnutrition (CONUT score ≥ 5 points) at admission. Ad = admission; CONUT = controlling nutritional status.

Figure S4. Combined outcome after discharge between patients with the raising and lowering of CONUT score during the index hospitalization. Note: All patients were divided into the two groups by the difference between CONUT score at admission and discharge; ΔCONUT = CONUT score at discharge – CONUT score at admission. CONUT = controlling nutritional status.

Figure S5. Composite outcome after discharge among the 4 subgroups categorized according to the CONUT scores at admission and discharge in patients with HFpEF or HFrEF CONUT = controlling nutritional status; HFrEF = heart failure with preserved left ventricular ejection fraction; HFpEF = heart failure with reduced ejection fraction.

References

1. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrioune E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP, Thiele H, Piepoli MF, Meta M, Maggiorno A, McMurray J, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G. Recommendations on prehospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 2015; 17: 544–558.

2. Shah NS, Molsberry R, Rana JS, Sidney S, Capewell S, O’Flaherty M, Carthenon M, Lloyd-Jones DM, Khan SS. Heterogeneous trends in burden of heart disease mortality by subtypes in the United States, 1999-2018: observational analysis of vital statistics. BMJ 2020; 370: m2688.

3. Suzuki A, Shiga T, Kawashiro N, Hagiwara N, Hagiwara N, Investigators H-HI. Changes in characteristics and outcomes in Japanese patients with heart failure from the 2000s to the 2010s: The HIJ-HF cohorts. J Cardiol 2020; 76: 132–138.

4. Desai AS, Claggett B, Pfeffer MA, Bello N, Finn PV, Granger CB, McMurray JJ, Pocock S, Swedberg K, Yusuf S, Solomon SD. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circ Heart Fail 2014; 7: 895–902.

5. Sze S, Pellicori P, Kazmi S, Rigby A, Cleland JGF, Wong K, Clark AL. Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure: A Comparison With Body Mass Index. JACC Heart Fail. 2018; 6: 476–486.

6. Agra Bermejo RM, Gonzalez Ferreiro R, Varela Roman A, Gomez Otero I, Kreidieh O, Conde Sabaris P, Rodriguez-Manero M, Mourre Gonzalez M, Seoane Blanco A, Virgos Lamela A, Garcia Castelo A, Gonzalez Juanatey JR. Nutritional status is related to heart failure severity and hospital readmissions in acute heart failure. Int J Cardiol 2017; 230: 108–114.

7. Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. Eur J Heart Fail 2015; 17: 884–892.

8. Nakagomi A, Kohashi K, Morisawa T, Kosugi M, Endoh I, Kusama Y, Atarashi H, Shimizu W. Nutritional Status is Associated with Inflammation and Predicts a Poor Outcome in Patients with Chronic Heart Failure. J Atheroscler Thromb 2016; 23: 713–727.

9. Ikwami N, Nagai T, Furukawa TA, Sugano Y, Honda S, Okada A, Asaumi Y, Aiba T, Naguchi T, Kusano K, Ogawa H, Yasuda S, Anzai T, Na DEFi. Prognostic value of malnutrition assessed by Controlling Nutritional Status score for long-term mortality in patients with acute heart failure. Int J Cardiol 2017; 230: 529–536.

10. Pittman JG, Cohen P. The Pathogenesis of Cardiac Cachexia. N Engl J Med. 1964; 271: 403–409 CONTD.

11. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999; 115: 836–847.

12. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050–1053.

13. Ignacio de Ulbarri J, Gonzalez-Madrono A, de Villar NG, Gonzalez P, Gonzalez B, Mancha A, Rodriguez F, Fernandez G. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 2005; 20: 38–45.

14. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441–1446.

15. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Kruecoff MW, Vranckx P, Windcker S, Gutip S, Serruys PW, Academic Research C. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation 2018; 137: 2653–2650.

16. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomin Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.

17. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GCM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCSD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute
and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37: 2129–2200.

18. Bouillanne O, Morineau G, Dupont C, Coulombe I, Vincent JP, Nicolas I, Benazeth S, Cynober L, Aussel C. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 2005; 82: 777–783.

19. Buzby GP, Mullen JL, Matthews DC, Hobs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg 1980; 139: 160–167.

20. Yoshihisa A, Kanno Y, Watanabe S, Yokokawa T, Abe S, Miyata M, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kuni H, Nakazato K, Suzuki H, Ishida T, Takeishi Y. Impact of nutritional indices on mortality in patients with heart failure. Open Heart. 2018; 5: e000730.

21. Mizobuchi K, Jujo K, Minami Y, Ishida I, Nakao M, Hagiwara N. The Baseline Nutritional Status Predicts Long-Term Mortality in Patients Undergoing Endovascular Therapy. Nutrients. 2019; 11: 1745.

22. Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, Yamamoto K. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 2013; 77: 705–711.

23. Kaneko H, Suzuki S, Goto M, Yuzawa Y, Arita T, Yagi N, Murata N, Kato Y, Kano H, Matsuno S, Otsuka T, Uejima T, Takai H, Oikawa Y, Kunihara T, Nakashima K, Kirigaya H, Sagara K, Sawada H, Aizawa T, Yajima J, Yamashita T. Geriatric nutritional risk index in hospitalized heart failure patients. Int J Cardiol. 2015; 181: 215–215.

24. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003; 107: 223–225.

25. O’Meara E, Clayton T, McIntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeifer MB, Committees G, Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006; 113: 986–994.

26. Cheng YL, Sung SH, Cheng HM, Hsu PF, Guo CY, Yu WC, Chen CH. Prognostic Nutritional Index and the Risk of Mortality in Patients With Acute Heart Failure. J Am Heart Assoc 2017; 6: 6.

27. Evans WE, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Loccisano G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr 2008; 27: 793–799.

28. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dreesman P, Fonseca C, Goudev A, Grande P, Gulstad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korowicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufeleberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Welde H, Wikstrand J, Group C. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–2261.

29. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G, Gissi HFI. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231–1239.

30. Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Dzauz MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tai J, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 185–266.